Digestive Drugs Market to surpass US$ 82,969.4 Million by 2030, Says Coherent Market Insights (CMI)

Burlingame, Feb. 22, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global digestive drugs market is estimated to be valued at US$ 52,594.8 Million in 2022 and is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Digestive Drugs Market:

Key companies operating in market are focusing on the approval of new therapeutic solutions, which is contributing to the market growth. For instance, in June 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa). It is a specific interleukin-23 (IL-23) inhibitor which is used for the treatment of adults with moderately to severely active Crohn's disease (CD). The SKYRIZI is a selectively blocks IL-23 by binding to its p19 subunit. The approved dosage for treatment of moderately to severely active Crohn's disease is 600 mg which is administered by intravenous infusion over at least one hour followed by 360 mg administered by subcutaneous injection.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5542

Digestive Drugs Market Report Coverage

Key Market Takeaways:

Global digestive drugs market is expected to exhibit a CAGR of 5.9% during the forecast period, owing to increasing research and development activities for the development of drugs which are used for treating gastric disorders. For instance, according to an August 2021, article published in Frontiers Media S.A., researchers are developing new prokinetic therapies for gastric motility disorders. Researchers are developing new prokinetic agents such as novel serotonergic 5-HT4 agonists, neurokinin NK1 antagonists and dopaminergic D2/3 antagonists among others. These targets improves gastric motility functions including neurogenesis, oxidative stress and inflammatory functions.

Among type, generic segment is expected to witness highest growth in the global digestive drugs market over the forecast period. The growth of generic segment can be attributed to factors such as launch of new products. For instance, in August 2021, Dr Reddy's Laboratories, an Indian multinational pharmaceutical company, launched generic Clidinium Bromide capsules and Chlordiazepoxide Hydrochloride in the U.S. These are used to treat stomach ulcers, irritable bowel syndrome and inflammation of the colon.

Competitive Landscape:

Key players operating in the global digestive drugs market include GlaxoSmithKline plc, AbbVie Inc. (Allergan), Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca plc, Marksans Pharma, Tillotts Pharma AG, Salix Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Merck & Co., Inc., Lexicon Pharmaceuticals, Inc., Bayer AG, Cadila Healthcare Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5542

Market Segmentation:

• Global Digestive Drugs Market, By Type
  • Branded
  • Generic
• Global Digestive Drugs Market, By Drug Class
  • 5-aminosalicylates
  • GI stimulants
  • Laxatives
  • Antacids
  • H2 Antagonists
  • Antidiarrheals
  • Others
• Global Digestive Drugs Market, By Route of Administration
  • Oral
  • Intravenous
  • Others
• Global Digestive Drugs Market, By Application
  • Gastroesophageal Reflux Disease (GERD)
  • Irritable Bowel Syndrome
  • Ulcerative Colitis
  • Others (Chronic diarrhoea, constipation etc.)
• Global Digestive Drugs Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Digestive Drugs Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
        

Related Market Intelligence Reports:

Clostridioides Difficile Infection Treatment Market, by Drug Type (Vancomycin, Metronidazole, Fidaxomicin, and Others (late phase drugs, etc.)), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030

Anti-Obesity Drug Market, By Mechanism of Action (Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs), By Prescription/Non- prescription (Prescription Drugs and OTC Drugs), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedIn | Twitter